Would immunization be the same without cross-reactivity?

Published: 9 December 2019| Version 1 | DOI: 10.17632/mwhr77zm7g.1
Ivo Vojtek,
Philippe Buchy,
Timothy Doherty,
Bernard Hoet


This video supports the published article Vojtek I, Buchy P, Doherty TM, Hoet B.Would immunization be the same without cross-reactivity? Vaccine. 2019;37(4):539-549. doi: 10.1016/j.vaccine.2018.12.005. In this article, we review the concepts of ‘cross-reactivity’ and ‘cross-protection’ which are both common and important from a public health perspective. Real-world cross-protection data are now available for several vaccines (e.g. those against diseases caused by human papillomavirus and rotavirus). Through this article, we reviewed the growing body of evidence to highlight the full impact of vaccines – beyond vaccine-type disease – that should be taken into consideration when assessing the full value of vaccination programs. With the advent of the next generation of vaccine technologies, we think cross-reactivity might become the solution to creating vaccines against highly antigenically and genetically diverse pathogens.



GlaxoSmithKline Biologicals SA


Vaccine, Immunization, Adjuvant, Disease Prevention